| Trial ID: | L2467 |
| Source ID: | NCT00565162
|
| Associated Drug: |
Insulin Glargine
|
| Title: |
Insulin Glargine, INITIATE Metabolic and Economic Outcomes of Lantus
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus
|
| Interventions: |
DRUG: Insulin Glargine
|
| Outcome Measures: |
Primary: Superiority is based on observing clinically significant difference in glycaemic control (> than or = to 0,5 % HbA1c). Programs are defined as equally successful if the HbA1c differs less than 0,5 %., HbA1c values at visits 1, 2, 5 and 10 |
|
| Sponsor/Collaborators: |
Sponsor: Sanofi
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
124
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2003-11
|
| Completion Date: |
2005-06
|
| Results First Posted: |
|
| Last Update Posted: |
2008-08-25
|
| Locations: |
Sanofi-Aventis, Helsinki, Finland|Sanofi-Aventis, Amsterdam, Netherlands|Sanofi-Aventis, Stockholm, Sweden|Sanofi-Aventis, Leicester, United Kingdom
|
| URL: |
https://clinicaltrials.gov/show/NCT00565162
|
